News


All series


All News

Valeant Pharmaceuticals has entered into an agreement to acquire B+L for $8.7 billion, which includes $4.2 billion in debt. The deal is expected to close in Q3, and B+L will retain its name.

The toric intraocular lens (IOL) provides a greater range, enhanced efficacy, more precise visual recovery for the cataract patient, and reduced potential of complications in a single surgery. Also, toric lenses provide the opportunity for optometrists to co-manage the patient’s recovery.